AstraZeneca inks kidney therapy deal worth up to $1.77B with China’s CSPC

PartnershipPositive

AI Analysis

Summary

AstraZeneca has signed a kidney therapy licensing deal with China's CSPC worth up to $1.77 billion. The agreement represents a significant partnership for AstraZeneca's kidney disease pipeline in the Chinese market.

Importance:7/10

Sentiment:

0.60

licensing dealpartnershipkidney therapyChinaM&A

Related Companies

$AZN

Read the original article

Published by Seeking Alpha Healthcare on July 2, 2026 12:02 PM

Read Original